has been cited by the following article(s):
|
[1]
|
Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus
|
|
Biomedicine & Pharmacotherapy,
2024 |
|
|
|
|
[2]
|
An overview of inflammation: pathways & gene therapy
|
|
International Journal of …,
2023 |
|
|
|
|
[3]
|
Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway
|
|
2021 |
|
|
|
|
[4]
|
Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes
|
|
2019 |
|
|
|
|
[5]
|
Protecting pancreatic β-cells against cytokines: Novel function of Islet Neogenesis Associated Protein (INGAP) and combinatorial treatment with NF-κB …
|
|
2018 |
|
|
|
|
[6]
|
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
|
|
Current Diabetes Reviews,
2017 |
|
|
|
|
[7]
|
Generation of Mesenchymal Stem Cells Expressing Islet Neogenesis-Associated Protein (INGAP)
|
|
2017 |
|
|
|
|
[8]
|
Therapeutic targets for management of periodontitis and diabetes
|
|
Current Pharmaceutical Design,
2016 |
|
|
|
|
[9]
|
Inflammatory Pathways Linked to β Cell Demise in Diabetes
|
|
Islets of Langerhans,
2015 |
|
|
|
|
[10]
|
Copia autorizada por CDR
|
|
Circulation,
2015 |
|
|
|
|
[11]
|
Skin barrier defects in atopic dermatitis
|
|
Current Allergy and Asthma Reports,
2014 |
|
|
|
|
[12]
|
Targeting inflammation in diabetes: Newer therapeutic options
|
|
World Journal of Diabetes,
2014 |
|
|
|
|
[13]
|
Islet inflammation: a unifying target for diabetes treatment?
|
|
Trends in Endocrinology & Metabolism,
2013 |
|
|
|
|
[14]
|
Detection of Islet β-Cell Death in Vivo by Multiplex PCR Analysis of Differentially Methylated DNA
|
|
Endocrinology,
2013 |
|
|
|
|
[15]
|
Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes
|
|
Endocrine Practice,
2013 |
|
|
|
|
[16]
|
Inflammatory pathways linked to beta cell demise in diabetes
|
|
Islets of Langerhans, 2. ed.,
2013 |
|
|
|
|
[17]
|
Sarah Tersey
|
|
|
|
|
|
|
[1]
|
Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus
Biomedicine & Pharmacotherapy,
2024
DOI:10.1016/j.biopha.2023.115958
|
|
|
|
|
[2]
|
Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway
Cytokine,
2021
DOI:10.1016/j.cyto.2020.155398
|
|
|
|
|
[3]
|
Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes
Molecular Pharmaceutics,
2019
DOI:10.1021/acs.molpharmaceut.9b00833
|
|
|
|
|
[4]
|
Islets of Langerhans
2015
DOI:10.1007/978-94-007-6686-0_30
|
|
|
|
|
[5]
|
Islets of Langerhans, 2. ed.
2014
DOI:10.1007/978-94-007-6884-0_30-2
|
|
|
|
|
[6]
|
Islet inflammation: a unifying target for diabetes treatment?
Trends in Endocrinology & Metabolism,
2013
DOI:10.1016/j.tem.2013.01.007
|
|
|
|
|
[7]
|
Distinctions Between the Islets of Mice and Men: Implications for New Therapies for Type 1 and 2 Diabetes
Endocrine Practice,
2013
DOI:10.4158/EP12138.RA
|
|
|
|